Myrcludex B is a drug against hepatitis B and hepatitis D.
Detailed description
The medication developed by DZIF scientists prevents hepatitis B viruses and hepatitis D viruses from entering liver cells. Co-infection of hepatitis B and hepatitis D presents the most serious form of viral hepatitis and was untreatable until then. Myrcludex B is a substance well tolerated by humans and it prevents viral reproduction.
The motto of this year's World Hepatitis Day, proclaimed annually on 28 July by the World Health Organisation (WHO), is “It's time to act". Hundreds of millions of people worldwide are affected by
Around 260 million people, more than three percent of the global population, are chronically infected with the hepatitis B virus (HBV); in the long term, this often leads to complications such as
Professor Stephan Urban and his team developed the first drug for hepatitis D at the Heidelberg University Hospital. So far, there has been no curative treatment – the number of chronically infected
Researchers have for the first time succeeded in conquering a chronic infection with the hepatitis B virus in a mouse model. The team showed in its publication, that T-cell therapy can provide a
